As we celebrate the rich histories and contributions of Asian American, Native Hawaiian, and Pacific Islander (AANHPI) communities this AANHPI Heritage Month, the Asian & Pacific Islander American Health Forum (APIAHF) shines a light on a grave health disparity within these diverse groups.
Cancer remains a particularly relentless adversary within our communities. It is the leading cause of death among AANHPIs since 2000 according to the CDC, representing 27% of all deaths in our communities. Recent data illustrates that lung (27%), liver (14%), and colorectal (11%) cancers emerge as the most common causes of cancer-related deaths among AANHPI men, while women face the highest mortality from lung (21%), breast (14%), and colorectal cancers (11%).
This significant toll presents a silent crisis that demands our immediate, united action, fueling our mission to ensure cancer equity — the pursuit of equitable access to cancer prevention, early detection, and quality care for every individual. To ensure health equity requires confronting the unique health disparities and recognizing the importance of disaggregated data within AANHPI subgroups. We believe that with tailored education and outreach that prioritizes precise, culturally responsive health strategies, many of these deaths could be prevented.
Yet, our communities face tough hurdles to early detection and treatment: inadequate insurance, cultural beliefs that can hinder seeking help, lack of education about prevention and treatment, and language barriers that make navigating healthcare a struggle. One in three adults in our communities have limited English proficiency, leading to a critical lack of cancer resources in languages accessible to them. These challenges are especially acute for our immigrant Southeast Asian and NHPI communities, highlighting the urgent need for support and information that truly speaks to them.
In 2023, APIAHF received PhRMA’s Collaborative Actions to Reach Equity (CAREs) grant to support our “Improving Cancer Outcomes in AANHPI Communities” initiative. Our strategy is two-fold: to boost education and awareness around cancer prevention and treatment and to expand access to life-saving cancer screenings. To achieve this effectively, it’s imperative that we approach AANHPI populations with culturally sensitive solutions that align with their lived experiences, ensuring we provide accessible and relevant support directly within their communities.
Through our network of over 250 CBOs, we’ve launched educational campaigns in numerous AANHPI languages that spotlight health disparities and key cancers that disproportionately affect our communities — such as breast, cervical, colorectal, gastric, ovarian, prostate, and liver — as well as emphasizing general preventative care. This outreach is designed to elevate awareness and stimulate informed discussions about prevention and treatment options among underserved and uninsured refugee, immigrant, migrant, and AANHPI individuals with limited English proficiency, as well as healthcare professionals across diverse care settings.
At APIAHF, we believe targeted efforts can foster significant transformations. As we honor our histories this AANHPI Heritage Month, let’s renew our dedication to a healthier future for our AANHPI communities by advocating for, educating about, and ensuring equitable cancer care.
Through collaborative, tailored strategies, we will not only bridge health gaps — we can create a legacy of health equity and empowerment as vibrant and inclusive as our heritage itself.
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
New study: HPV vaccination helps prevent cervical cancer deaths
America's cancer research progress is real and worth protecting
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
Advancing patient care: A look at new medicines approved in 2025
CAREs 2025: Supporting community-based solutions that improve access to medicines
New analysis finds 340B hospitals push patients toward costly care to boost profits
Price setting policies put cancer gains in jeopardy
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Guest Perspective: Prioritize Innovative Care
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
Recent events highlight progress on health equity
ICYMI: PhRMA’s 4th Annual Pathways to Success: Virtual STEM Career Expo
The importance of partnership: A conversation with Takeda
Hispanic Heritage Month: Fighting for Hispanic patients
PhRMA awards grants to 2024 Annual Pathways to Success: Virtual STEM Career Expo Partners
The future of oncology R&D lies in policymakers’ hands
Showcasing the promise of biopharma at ASCO 2024
How government price setting fails to address systemic health care inequities
Women’s Health Month: A conversation with Sage
New analysis: Accelerated approval pathway is changing lives in underserved communities
The impact of innovative medicines: A caregiver's perspective
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
Three things to know about antibody drug conjugates
PhRMA provides grant funding to support the Morehouse School of Medicine Satcher Health Leadership Institute’s Health Equity Tra
The IRA’s pill penalty threatens the future of oncology R&D
New Report: 1,600 cancer treatments and vaccines in clinical development
New social determinants of health simulation explores structural barriers patients face accessing and affording medicines
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
PhRMA awards grants to 2023 Annual Pathways to Success Graduate Summit Partners
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
ASCO 2023: Protecting our progress in the fight against cancer
Highlights from ASCO 2023
PhRMA awards grant to Emerson Diversity Health Foundation
PhRMA Otorga Beca a la “Emerson Diversity Health Foundation”
IRA Impacts: Cancer treatment research and development
State policymakers can protect American innovation and help Americans live longer, healthier lives
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
Using traditional HTAs to determine coverage threatens patient access to medicine
Traditional HTAs keep diverse patients out of the conversation
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Traditional HTA methods treat everyone like the “average” patient
Protecting treatment advances for breast cancer
You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities
Key takeaways from ASCO's annual meeting
Potential gene therapies bring hope to patients with sickle cell disease
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Report: More than 500 medicines in development to treat disorders of the blood
Stephanie Dyson of BMS on reducing health disparities
Sharing rebates can save Americans with diabetes 500 each year and improve adherence
4 things to know about biopharmaceutical efforts to fight cancer
New data show continued decline in death rates for cancer patients related to treatment advances
Announcing CAREs Grant Round 4
Announcing CAREs Grant Round 4
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
Recognizing National Immunization Awareness Month
PhRMA awards $75,000 to fund initiatives to reduce health inequities
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
PhRMA hosts first stakeholder workshop on clinical trial diversity
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
PhRMA member companies share how they are improving clinical trial diversity
Action needed to preserve the six protected classes
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
ICYMI: Cancer death rate continues decline due to advances in treatment
Paper finds gaps in health data are a barrier to health equity
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
Increasing diversity at investigator sites could increase minority participation in clinical trials
Report highlights biopharmaceutical industry’s commitment to D&I
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
Report: More than 1,300 medicines and vaccines in development to help fight cancer
PhRMA CAREs Grant request for proposals: Addressing racial disparities in medication utilization and adherence
Committing to diversity, equity and inclusion: A call to action for clinical trials
Just released: PhRMA members’ new clinical trial diversity principles
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
Guest Post: Honoring Hispanic Heritage Month by taking action on health equity
Sharing rebates can improve access to medicines and increase health equity
PhRMA will continue to advocate for equity within our industry
Three ways the pharmaceutical industry can positively impact health equity
Guest Post: Amgen Foundation stands for equal opportunities in STEM learning
Systemic racism is as real as any disease, and our industry is not immune
New report explores setbacks that bring future cancer success stories
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
PhRMA awards $100,000 to fund projects that address health inequalities
Observing National Minority Health Month in the age of COVID-19
Cancer medicines cost twice as much at hospitals, study finds
Saving kids and dogs from shared cancers
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Protect your health: Important disaster preparedness tips for Harvey and Irma
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
Medicines have significantly increased chances of cancer survival around the globe
ICYMI: Report highlights overall decrease in cancer death rates
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
Championing cancer equity: Our drive for healthier AANHPI communities
Cancer
Health Equity
Championing cancer equity: Our drive for healthier AANHPI communities
Championing cancer equity: Our drive for healthier AANHPI communities